Clinical trials: Psoriasis Patients
Plaque Psoriasis Vulgaris
Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis
The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.
- Trial name
- DERMIS (NCT03310320)
- Testing
- AZD0284 oral solution 2.5 mg/mL
- Where
- 4 sites in Denmark
- Volunteers
- 9 people
- Sponsor
- AstraZeneca
Psoriasis
A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
This single arm study will evaluate the efficacy and safety of sequential treatment with Diavobet (betamethasone propionate 0.5mg/g plus calcipotriol hydrate 50 micrograms/g) once daily for 4 weeks followed by Daivonex…
- Trial name
- NCT00437619
- Testing
- calcipotriol hydrate [Daivonex]
- Where
- 10 sites in Brazil
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
Psoriasis
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment
The aim of this study was to evaluate the pharmacokinetics of Hemay005 tablets in subjects with mild to moderate renal impairment and normal renal function, and to provide a basis for the formulation of clinical medication…
- Trial name
- NCT06380153
- Testing
- Hemay005
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
Chronic Plaque-type Psoriasis
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body…
- Trial name
- NCT00941031
- Testing
- AIN457, AIN457A
- Where
- 62 sites in United States, France and 5 more
- Volunteers
- 404 people
- Sponsor
- Novartis Pharmaceuticals
Generalized Pustular Psoriasis
Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis
The primary and secondary objectives are to respectively monitor the safety and effectiveness of Spesolimab IV in Korean patients with flares with generalized pustular psoriasis (GPP) in a routine medical practice.
- Trial name
- NCT06886009
- Testing
- Spevigo®
- Where
- 4 sites in South Korea
- Sponsor
- Boehringer Ingelheim
Plaque Psoriasis
A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis
IMO 8400 is a second-generation oligonucleotide antagonist of endosomal Toll-like receptors (TLR) 7, TLR8 and TLR9. These TLR react to complexes of exogenous nucleic acids (as might be encountered during infection) and endogenous…
- Trial name
- 8400-201 (NCT01899729)
- Testing
- IMO-8400 Regimen 1, IMO-8400 Regimen 2, IMO-8400 Regimen 3
- Where
- Netherlands
- Volunteers
- 46 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Plaque Psoriasis
A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
The objectives of this study are to evaluate the therapeutic efficacy and safety of DSXS and a Placebo in patients with moderate to severe scalp psoriasis.
- Trial name
- NCT02413229
- Testing
- DSXS1411
- Volunteers
- 151 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Plaque Type Psorisis
Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis
To compare the safety and efficacy of the test (Tapinarof Cream 1%), placebo (vehicle cream) and reference VTAMA® (Tapinarof Cream 1%) treatments to demonstrate clinical equivalence in patients with plaque psoriasis.
- Trial name
- NCT06742957
- Testing
- Tapinarof Cream 1%, VTAMA®
- Where
- 26 sites in United States
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Psoriasis, Psoriasis Vulgaris
Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis
Psoriasis, the most prevalent autoimmune disease in the U.S., manifests with plaque type psoriasis vulgaris with lesions localized to the scalp, postauricular region, face, diaper area, elbows, and knees.
- Trial name
- NCT03069144
- Testing
- HAT1 topical solution, Calcipotriol
- Volunteers
- 28 people
- Sponsor
- Haus Bioceuticals
Psoriasis
Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
The objective of this study is to demonstrate that desoximetasone 0.25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01206660
- Testing
- Desoximetasone Spray 0.25%
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
A Study of Ixekizumab in Participants With Plaque Psoriasis
This study is known as a "drug interaction study." The purpose is to learn about how ixekizumab may affect the blood levels of a mixture of commonly used drugs (caffeine, omeprazole, warfarin, dextromethorphan, and midazolam)…
- Trial name
- NCT02993471
- Testing
- Drug Cocktail, Ixekizumab
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Psoriasis
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis
The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with plaque-type psoriasis.
- Trial name
- NCT00230529
- Testing
- infliximab
- Volunteers
- 249 people
- Sponsor
- Centocor, Inc.
Plaque Psoriasis
Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients
This study provided a comparison of secukinumab to placebo with respect to skin inflammation as measured by skin exams in comparison to skin biopsies, adipose tissue and blood sample analyses.
- Trial name
- ObePso-S (NCT03055494)
- Testing
- Secukinumab
- Where
- 15 sites in United States
- Volunteers
- 102 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Sjögren's Disease
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis, Psoriatic Arthritis
- Trial name
- NCT07791199
- Testing
- Deucravacitinib
- Volunteers
- 2,300 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis
To assess the influence of risankizumab on kinetics of cytochrome P450 (CYP) probe drugs as a means of predicting drug-drug interactions.
- Trial name
- NCT02772601
- Testing
- Caffeine, Warfarin, Omeprazole
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- AbbVie
Psoriatic Arthritis
A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis
This is a Phase II, prospective, multicenter, randomized, double-blind, placebo-controlled, dose finding trial in parallel-groups with primary endpoint at Week 16 (visit V9) to investigate the efficacy, tolerability, safety…
- Trial name
- NCT04713072
- Testing
- ABY-035
- Where
- 32 sites in Austria, Belgium and 5 more
- Volunteers
- 129 people
- Sponsor
- ACELYRIN Inc.
Psoriatic Arthritis
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are…
- Trial name
- EXCEED 1 (NCT02745080)
- Testing
- Secukinumab, Adalimumab
- Where
- 156 sites in United States, Australia and 24 more
- Volunteers
- 853 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, dose-escalation Phase Ib study to evaluate the safety, tolerability, and pharmacokinetics of HB0017 following multiple dose in patients with moderate to severe plaque…
- Trial name
- NCT05442788
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Chronic Plaque Psoriasis
A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545
-To evaluate the safety and tolerability of a multiple doses of this drug in adult patients.
- Trial name
- CP145 (NCT00472758)
- Testing
- MEDI 545
- Where
- 3 sites in Canada
- Volunteers
- 40 people
- Sponsor
- MedImmune LLC
Arthritis, Psoriatic
A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis
This study is open to adults with active psoriatic arthritis who have tender and swollen joints. The purpose of this study is to find out whether a medicine called BI 730357 helps to reduce symptoms and to prevent damage to…
- Trial name
- NCT04680676
- Testing
- BI 730357
- Sponsor
- Boehringer Ingelheim